Cargando…
P63 and P73 Activation in Cancers with p53 Mutation
The members of the p53 family comprise p53, p63, and p73, and full-length isoforms of the p53 family have a tumor suppressor function. However, p53, but not p63 or p73, has a high mutation rate in cancers causing it to lose its tumor suppressor function. The top and second-most prevalent p53 mutatio...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313412/ https://www.ncbi.nlm.nih.gov/pubmed/35884795 http://dx.doi.org/10.3390/biomedicines10071490 |
_version_ | 1784754073682051072 |
---|---|
author | Cai, Bi-He Hsu, Yun-Chien Yeh, Fang-Yu Lin, Yu-Rou Lu, Rui-Yu Yu, Si-Jie Shaw, Jei-Fu Wu, Ming-Han Tsai, Yi-Zhen Lin, Ying-Chen Bai, Zhi-Yu Shih, Yu-Chen Hsu, Yi-Chiang Liao, Ruo-Yu Kuo, Wei-Hsin Hsu, Chao-Tien Lien, Ching-Feng Chen, Chia-Chi |
author_facet | Cai, Bi-He Hsu, Yun-Chien Yeh, Fang-Yu Lin, Yu-Rou Lu, Rui-Yu Yu, Si-Jie Shaw, Jei-Fu Wu, Ming-Han Tsai, Yi-Zhen Lin, Ying-Chen Bai, Zhi-Yu Shih, Yu-Chen Hsu, Yi-Chiang Liao, Ruo-Yu Kuo, Wei-Hsin Hsu, Chao-Tien Lien, Ching-Feng Chen, Chia-Chi |
author_sort | Cai, Bi-He |
collection | PubMed |
description | The members of the p53 family comprise p53, p63, and p73, and full-length isoforms of the p53 family have a tumor suppressor function. However, p53, but not p63 or p73, has a high mutation rate in cancers causing it to lose its tumor suppressor function. The top and second-most prevalent p53 mutations are missense and nonsense mutations, respectively. In this review, we discuss possible drug therapies for nonsense mutation and a missense mutation in p53. p63 and p73 activators may be able to replace mutant p53 and act as anti-cancer drugs. Herein, these p63 and p73 activators are summarized and how to improve these activator responses, particularly focusing on p53 gain-of-function mutants, is discussed. |
format | Online Article Text |
id | pubmed-9313412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93134122022-07-26 P63 and P73 Activation in Cancers with p53 Mutation Cai, Bi-He Hsu, Yun-Chien Yeh, Fang-Yu Lin, Yu-Rou Lu, Rui-Yu Yu, Si-Jie Shaw, Jei-Fu Wu, Ming-Han Tsai, Yi-Zhen Lin, Ying-Chen Bai, Zhi-Yu Shih, Yu-Chen Hsu, Yi-Chiang Liao, Ruo-Yu Kuo, Wei-Hsin Hsu, Chao-Tien Lien, Ching-Feng Chen, Chia-Chi Biomedicines Review The members of the p53 family comprise p53, p63, and p73, and full-length isoforms of the p53 family have a tumor suppressor function. However, p53, but not p63 or p73, has a high mutation rate in cancers causing it to lose its tumor suppressor function. The top and second-most prevalent p53 mutations are missense and nonsense mutations, respectively. In this review, we discuss possible drug therapies for nonsense mutation and a missense mutation in p53. p63 and p73 activators may be able to replace mutant p53 and act as anti-cancer drugs. Herein, these p63 and p73 activators are summarized and how to improve these activator responses, particularly focusing on p53 gain-of-function mutants, is discussed. MDPI 2022-06-23 /pmc/articles/PMC9313412/ /pubmed/35884795 http://dx.doi.org/10.3390/biomedicines10071490 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Cai, Bi-He Hsu, Yun-Chien Yeh, Fang-Yu Lin, Yu-Rou Lu, Rui-Yu Yu, Si-Jie Shaw, Jei-Fu Wu, Ming-Han Tsai, Yi-Zhen Lin, Ying-Chen Bai, Zhi-Yu Shih, Yu-Chen Hsu, Yi-Chiang Liao, Ruo-Yu Kuo, Wei-Hsin Hsu, Chao-Tien Lien, Ching-Feng Chen, Chia-Chi P63 and P73 Activation in Cancers with p53 Mutation |
title | P63 and P73 Activation in Cancers with p53 Mutation |
title_full | P63 and P73 Activation in Cancers with p53 Mutation |
title_fullStr | P63 and P73 Activation in Cancers with p53 Mutation |
title_full_unstemmed | P63 and P73 Activation in Cancers with p53 Mutation |
title_short | P63 and P73 Activation in Cancers with p53 Mutation |
title_sort | p63 and p73 activation in cancers with p53 mutation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313412/ https://www.ncbi.nlm.nih.gov/pubmed/35884795 http://dx.doi.org/10.3390/biomedicines10071490 |
work_keys_str_mv | AT caibihe p63andp73activationincancerswithp53mutation AT hsuyunchien p63andp73activationincancerswithp53mutation AT yehfangyu p63andp73activationincancerswithp53mutation AT linyurou p63andp73activationincancerswithp53mutation AT luruiyu p63andp73activationincancerswithp53mutation AT yusijie p63andp73activationincancerswithp53mutation AT shawjeifu p63andp73activationincancerswithp53mutation AT wuminghan p63andp73activationincancerswithp53mutation AT tsaiyizhen p63andp73activationincancerswithp53mutation AT linyingchen p63andp73activationincancerswithp53mutation AT baizhiyu p63andp73activationincancerswithp53mutation AT shihyuchen p63andp73activationincancerswithp53mutation AT hsuyichiang p63andp73activationincancerswithp53mutation AT liaoruoyu p63andp73activationincancerswithp53mutation AT kuoweihsin p63andp73activationincancerswithp53mutation AT hsuchaotien p63andp73activationincancerswithp53mutation AT lienchingfeng p63andp73activationincancerswithp53mutation AT chenchiachi p63andp73activationincancerswithp53mutation |